Am J Hematol:成人镰状细胞病患者慢性器官损害的前瞻性评估

2017-07-31 xiaoxiao MedSci原创

镰状细胞病(SCD)的器官损害是疾病严重程度和预后的关键决定因素。在以前的研究中,研究人员分析了成人镰状细胞病患者相关的器官损害和并发症的患病率。本研究中,研究人员报告了对成人镰状细胞病患者进行7年随访的研究数据。本研究中的所有患者 (n = 104)都来自2006年的初步分析,研究人员对他们进行了随访。患者每半年接受一次体检,包括SCD相关器官损害和并发症(尿微量白蛋白、肾功能衰竭、三尖瓣反流[

镰状细胞病(SCD)的器官损害是疾病严重程度和预后的关键决定因素。在以前的研究中,研究人员分析了成人镰状细胞病患者相关的器官损害和并发症的患病率。本研究中,研究人员报告了对成人镰状细胞病患者进行7年随访的研究数据。

本研究中的所有患者 (n = 104)都来自2006年的初步分析,研究人员对他们进行了随访。患者每半年接受一次体检,包括SCD相关器官损害和并发症(尿微量白蛋白、肾功能衰竭、三尖瓣反流[TRV]流速增快[≥2.5米/秒]、视网膜病变、铁过载、胆石症、缺血性坏死、下肢溃疡、急性胸部综合征[ACS]、中风、因血管阻塞性危象[VOC]导致的阴茎异常勃起)。

经过7年的随访,股骨头缺血性坏死(12.5%-20.4%)、肾功能衰竭(6.7%-23.4%)、视网膜病变(39.7%-53.8%)的患病率在所有组中均有进展。在HbSS/HbSβ0-地中海贫血的患者中也观察到了微量白蛋白尿(34%~45%)和TRV流速增快(从40%到48%),而胆石症、阴茎异常勃起、中风或慢性溃疡却没有明显进展。在HbSS/HbSβ0-地中海贫血的患者中,至少出现过一次ACS发作的患者的比例从32%增加到49.1%。

总之,在这项前瞻性队列研究中,在随访7年(全面的护理)后,62%的镰状细胞病患者出现了一个SCD相关的并发症。虽然血管阻塞性危象的住院率依然保持稳定,但多种形式的器官损害大幅度增加。这些发现强调在SCD患者的治疗中,除了要筛查VOC,还需要继续筛查其它器官损害。

原始出处:

van Tuijn CFJ, Schimmel M,et al.Prospective evaluation of chronic organ damage in adult sickle cell patients: A seven-year follow-up study.Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24855. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693903, encodeId=a2421693903e1, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Jul 09 13:31:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006394, encodeId=fcca20063941c, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 18 09:31:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317341, encodeId=41d6131e341e3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615482, encodeId=4976161548278, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228562, encodeId=ec0f228562b1, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jul 31 21:25:40 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693903, encodeId=a2421693903e1, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Jul 09 13:31:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006394, encodeId=fcca20063941c, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 18 09:31:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317341, encodeId=41d6131e341e3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615482, encodeId=4976161548278, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228562, encodeId=ec0f228562b1, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jul 31 21:25:40 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693903, encodeId=a2421693903e1, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Jul 09 13:31:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006394, encodeId=fcca20063941c, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 18 09:31:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317341, encodeId=41d6131e341e3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615482, encodeId=4976161548278, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228562, encodeId=ec0f228562b1, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jul 31 21:25:40 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-08-02 fengyi812
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693903, encodeId=a2421693903e1, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Jul 09 13:31:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006394, encodeId=fcca20063941c, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 18 09:31:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317341, encodeId=41d6131e341e3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615482, encodeId=4976161548278, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228562, encodeId=ec0f228562b1, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jul 31 21:25:40 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1693903, encodeId=a2421693903e1, content=<a href='/topic/show?id=48a140299ae' target=_blank style='color:#2F92EE;'>#器官损害#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40299, encryptionId=48a140299ae, topicName=器官损害)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdcd29484210, createdName=lujian, createdTime=Mon Jul 09 13:31:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006394, encodeId=fcca20063941c, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Mon Dec 18 09:31:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317341, encodeId=41d6131e341e3, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615482, encodeId=4976161548278, content=<a href='/topic/show?id=280196865f7' target=_blank style='color:#2F92EE;'>#镰状细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96865, encryptionId=280196865f7, topicName=镰状细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb4819654385, createdName=1508842480_96220443, createdTime=Wed Aug 02 11:31:00 CST 2017, time=2017-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=228562, encodeId=ec0f228562b1, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jul 31 21:25:40 CST 2017, time=2017-07-31, status=1, ipAttribution=)]
    2017-07-31 1e0f8808m18(暂无匿称)

    学习了,谢谢分享。

    0

相关资讯

镰状细胞贫血症的基因治疗,奇迹还是炒作?

对于镰状细胞贫血症,唯一的治疗方法是干细胞或骨髓移植,不过,找到匹配的供体又谈何容易?幸运的是,这种由单个突变引起的疾病特别适合基因治疗。过去几十年,基因治疗一直炒得很热,那么进展究竟如何?

Haematologica:雷帕霉素或能治疗获得性再生障碍性贫血

获得性再生障碍性贫血(acquired aplastic anemia)是一种获得性骨髓造血功能衰竭症。主要表现为骨髓造血功能低下,全血细胞减少和贫血、出血、感染综合症,免疫抑制治疗有效。大多数再生障碍性贫血患者对免疫抑制治疗的反应通常表现为抗胸腺细胞球蛋白和环孢霉素A,但有些患者出现环孢素脱瘾复发或需要长期服用环孢霉素维持血细胞计数。在本研究中,来自美国的研究人员探讨了雷帕霉素作为一种新的或替代

Haematologica:贫血的诊断不应只根据血红蛋白浓度,还应结合血浆容量

在实践中,临床医生普遍认为贫血(在非妊娠女性:血红蛋白浓度<120 g/L;男性<130 g/L)是由于血红蛋白合成受损以及红细胞丢失或破坏增加。极少数与血浆容量的增加导致的循环总血红蛋白浓度的增加有关。但这影响大吗?研究人员在人群中探讨了这个问题,使用优化的一氧化碳吸入法测定血红蛋白浓度,从而计算出在健康志愿者、手术患者以及炎症性肠病、慢性肝脏疾病或心脏衰竭患者的血浆容量。研究共纳入了109名参

Am J Hematol:神经参与了镰状细胞性贫血患者并发血管阻塞性危象的过程

镰状细胞性贫血(SCD)是一种遗传性血液系统疾病,易并发血管阻塞性危象(VOC),特别是血管阻塞性疼痛危象,相应治疗方案极少。镰状细胞性贫血发生VOC时,血小板调节细胞间粘附和血栓形成,暗示抗血小板药物可以缓解VOC。对SCD患者的研究指出,VOC可由压力、寒冷和疼痛本身诱导。研究人员猜测,疼痛会导致神经介导的血管收缩,减少局部血流量,促进微血管的镰状细胞的变性。因此,研究人员用体积描记法和激光多

JAMA Intern Med:贫血老年男性进行睾酮治疗能否获益?

轻度贫血且睾酮水平较低的男性进行睾酮治疗能改善其贫血状况吗?2017年4月,发表在《JAMA Intern Med.》的一项双盲、安慰剂对照试验结果表明,睾酮水平较低和不明原因贫血老年男性进行睾酮治疗相比安慰剂更能纠正贫血。该治疗也比安慰剂更能纠正男性原因明确的贫血,如缺铁性贫血。重要性:三分之一的老年男性贫血找不出公认的病因。目的:考察年龄在65岁或以上,睾酮水平明确较低,原因不明贫血的男性进行

Anaesth Intensive Care:全麻下超快速输入铁麦芽糖治疗铁缺乏是安全的

本研究旨在评估全麻期间超快速(15分钟)输入铁麦芽糖对治疗铁缺乏患者的有效性和安全性。研究人员进行了一项前瞻性干预非随机研究,共纳入了99名缺铁有或无贫血表现的成人患者。在超过15分钟的麻醉维持阶段,如果不贫血患者输入500毫克铁麦芽糖,贫血则输入1000毫克。六周评估患者的血流动力学稳定性,立即或延迟铁相关的副作用和疗效。铁麦芽糖输入前中后明显地低血压或血管加压素的需求并无明显差异。术中无严重并